Maharashtra FDA cancelled Cipla's Pune C&F unit drug sale licenses due to serious storage and recall issues. Inspectors found unauthorized claims on Reactin Plus Tablets packaging and seized stock valued at over eleven lakh rupees. The company failed to fully comply with market recall directions and address further distribution system discrepancies. Cipla Pharma & Life Sciences is contesting the order, stating the matter is currently sub judice.